Re-treatment 225Ac-J591 for mCRPC

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 29, 2020

Primary Completion Date

August 31, 2023

Study Completion Date

May 31, 2024

Conditions
Prostate Cancer
Interventions
DRUG

225Ac-J591

In this study, subject enrollment will be done in a re-treatment design. A single dose of 225Ac-J591 given at the specified dose per cohort. The initial planned dose level will be determined based upon prior radioactivity exposure level. Those with moderate exposure (up to 30 GBq of 177Lu) will start with 65 KBq/Kg and those with heavy prior exposure (more than 30 Gbq of 177Lu or any 225Ac) will start with 50 KBq/Kg.

Trial Locations (2)

10065

Weill Cornell Medicine, New York

11215

Brooklyn Methodist Hospital - New York Presbyterian, Brooklyn

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER

NCT04576871 - Re-treatment 225Ac-J591 for mCRPC | Biotech Hunter | Biotech Hunter